Show simple item record

dc.contributor.authorMiddleton, G
dc.contributor.authorBrock, K
dc.contributor.authorSummers, Yvonne J
dc.contributor.authorConnibear, J
dc.contributor.authorShah, R
dc.contributor.authorOttensmeier, C
dc.contributor.authorShaw, P
dc.contributor.authorMing-Lee, S
dc.contributor.authorPopat, S
dc.contributor.authorBarrie, C
dc.contributor.authorBarone, G
dc.contributor.authorMant, R
dc.contributor.authorSavage, J
dc.contributor.authorBillingham, L
dc.date.accessioned2019-04-29T09:49:02Z
dc.date.available2019-04-29T09:49:02Z
dc.date.issued2018en
dc.identifier.citationMiddleton G, Brock K, Summers Y, Connibear J, Shah R, Ottensmeier C, et al. 1384PD Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): results of the PePS2 trial. Ann Oncol. 2018;29(suppl_8):497.en
dc.identifier.doi10.1093/annonc/mdy292.007en
dc.identifier.urihttp://hdl.handle.net/10541/621812
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy292.007en
dc.titlePembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): results of the PePS2 trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-04-20T12:00:11Z


Files in this item

Thumbnail
Name:
561664.pdf
Size:
91.22Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record